New Commercial Partnership for NeuroVocalix
(WorldNews Health)

Cambridge Cognition Holdings Plc (`Cambridge Cognition` or the `Company`) New Commercial Partnership and Further Scientific Validation for NeuroVocalixTM Cambridge, UK, 19 July 2019: Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the second commercial partnership with a leading pharmaceutical company, for its NeuroVocalixTM platform. NeuroVocalixTM is a unique voice biomarker technology and the product was launched last year and recently presented ground-breaking demonstrable evidence of the potential at a major global Alzheimer`s conference. Verbal neuropsychological tests are widely used in cognitive...